Dr. Reddy’s Laboratories gets Health Canada nod for generic Semaglutide injection
Dr. Reddy’s Laboratories has received approval from Health Canada for its generic Semaglutide Injection, becoming the first company to do so in Canada. This approval covers both the 2 mg and 4 mg pen formulations of the drug, which is used to treat Type 2 diabetes. The company aims to provide an important treatment option for the approximately 3.9 million Canadians diagnosed with diabetes.
- ▪Dr. Reddy’s Laboratories has received a Notice of Compliance from Health Canada for its generic Semaglutide Injection.
- ▪The approval includes 2 mg and 4 mg pen formulations of the drug.
- ▪Canada is the second-largest market for Semaglutide, with around 3.9 million people diagnosed with diabetes.
Opening excerpt (first ~120 words) tap to expand
Dr. Reddy’s Laboratories has received a Notice of Compliance (NOC) from Health Canada for its generic Semaglutide Injection. Sun Pharma, Dr. Reddy’s, Zydus, Glenmark roll out generic SemaglutideIt has become the first company to receive the market authorisation for generic Semaglutide Injection in Canada, ahead of Health Canada’s review target date. The authorisation covers the 2 mg/pen (1.34 mg/mL) and 4 mg/pen (1.34 mg/mL).Canada is recognised as the world’s second-largest market for Semaglutide, Dr. Reddy’s said, citing IQVIA MAT Q3 2025 numbers. Dr. Reddy’s biologics unit gets U.S. FDA queriesWith launch preparations under way, it is well-positioned to bring the “important treatment option available to Canadian patients”.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at The Hindu — Top.
Discussion
0 commentsMore from The Hindu — Top
